Combining theranostic/particle therapy with immunotherapy for the treatment of GU malignancies-Reference-Cited by-同舟云学术

Combining theranostic/particle therapy with immunotherapy for the treatment of GU malignancies

Published:2023-12-13 Issue: Volume: Page:
ISSN:2688-4526
Container-title:BJUI Compass
language:en
Short-container-title:BJUI Compass

Author:

Skalina Karin A.¹^ORCID,Małachowska Beata¹^ORCID,Sindhu Kunal K.²,Thompson Marcher³,Nehlsen Anthony D.²,Salgado Lucas Resende²,Dovey Zachary⁴^ORCID,Hasan Shaakir⁵,Guha Chandan¹,Tang Justin¹

Affiliation:

1. Department of Radiation Oncology Montefiore Medical Center/Albert Einstein College of Medicine Bronx New York USA

2. Department of Radiation Oncology Icahn School of Medicine at Mount Sinai New York New York USA

3. Department of Radiation Oncology AIS Cancer Center/Adventist Health Bakersfield California USA

4. Department of Urology Icahn School of Medicine at Mount Sinai New York New York USA

5. New York Proton Center New York New York USA

Abstract

AbstractParticle therapy and radiopharmaceuticals are emerging fields in the treatment of genitourinary cancers. With these novel techniques and the ever‐growing immunotherapy options, the combinations of these therapies have the potential to improve current cancer cure rates. However, the most effective sequence and combination of these therapies is unknown and is a question that is actively being explored in multiple ongoing clinical trials. Here, we review the immunological effects of particle therapy and the available radiopharmaceuticals and discuss how best to combine these therapies.

Publisher

Wiley

Subject

General Medicine

Reference97 articles.

1. Whole Body Irradiation—Radiobiology or Medicine?

2. The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer

3. Combinatorial approach of immuno‐proton therapy in cancer: Rationale and potential impact

4. Repurposing Radiation Therapy for Immuno-oncology

5. Immune recognition of irradiated cancer cells